• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. International Journal of Pharmacology
  2. Vol 13 (7), 2017
  3. 773-784
  • Issues
    Online First Current Issue All Issues

International Journal of Pharmacology

Year: 2017 | Volume: 13 | Issue: 7 | Page No.: 773-784
DOI: 10.3923/ijp.2017.773.784

Facebook Twitter Reddit Linkedin E-mail
ASCI
Review Article

Drug Discovery Processes to Drug Targeting Mechanisms

Faheem Maqbool
School of Pharmacy, Pharmacy Australia Centre of Excellence, University of Queensland, Brisbane, QLD 4102, Australia

Amman Abid
Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan

Ishtiaq Ahmed
School of Medical Science, Gold coast campus, Griffith University, Southport QLD 4222, Australia

Drug discovery in different time frames provides a reflection in the struggle of scientists to generate synthetic products from a natural source. The complex processes exist in the development of the new drug from novel ideas. The duration may vary 10-15 year with estimation cost of $1.5 billion. The stratification of different assays involved in development phase leads to the acceptability of drug molecule. In the discovery phase, implementation of powerful techniques such as combinatorial chemistry and molecular modeling has also participated in the identification of drug target molecules. The advancement in molecular biology especially genomic science has also imparted a profound role in the discovery phase. However, with bioinformatics branch, it allows us to derive more suitable points for attacking the drug molecule in different disease conditions. However, the review will describe the preclinical stages, identification and validation of target through HTS (high throughput screening assay) and finally approval of drug molecule for further clinical development.
PDF Fulltext XML References Citation

How to cite this article

Faheem Maqbool, Amman Abid and Ishtiaq Ahmed, 2017. Drug Discovery Processes to Drug Targeting Mechanisms. International Journal of Pharmacology, 13: 773-784.

DOI: 10.3923/ijp.2017.773.784

URL: https://scialert.net/abstract/?doi=ijp.2017.773.784

Comments


Muhammad Ahmad Reply
04 October, 2019

very effective

Leave a Comment


Your email address will not be published. Required fields are marked *

Article Trend



Total views 3326

References


  1. Maqbool, F., H. Bahadar and M. Abdollahi, 2014. Science for the benefits of all: The way from idea to product. J. Med. Hypotheses Ideas, 8: 74-77.
    CrossRefDirect Link

  2. Hughes, J.P., S. Rees, S.B. Kalindjian and K.L. Philpott, 2011. Principles of early drug discovery. Br. J. Pharmacol., 162: 1239-1249.
    CrossRefDirect Link

  3. Chin, Y.W., M.J. Balunas, H.B. Chai and A.D. Kinghorn, 2006. Drug discovery from natural sources. AAPS J., 8: E239-E253.
    CrossRefPubMedDirect Link

  4. Zhang, M.Q. and B. Wilkinson, 2007. Drug discovery beyond the 'rule-of-five'. Curr. Opin. Biotechnol., 18: 478-488.
    CrossRefDirect Link

  5. Cragg, G.M. and D.J. Newman, 2005. Biodiversity: A continuing source of novel drug leads. Pure Appl. Chem., 77: 7-24.
    CrossRefDirect Link

  6. Gupta, P. and K.H. Lee, 2007. Genomics and proteomics in process development: opportunities and challenges. Trends Biotechnol., 25: 324-330.
    CrossRefDirect Link

  7. Ahn, N.G. and A.H.J. Wang, 2008. Proteomics and genomics: Perspectives on drug and target discovery. Curr. Opin. Chem. Biol., 12: 1-3.
    CrossRefDirect Link

  8. Lee, J.A., M.T. Uhlik, C.M. Moxham, D. Tomandl and D.J. Sall, 2012. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J. Med. Chem., 55: 4527-4538.
    CrossRefDirect Link

  9. Swinney, D.C. and J. Anthony, 2011. How were new medicines discovered? Nat. Rev. Drug Discov., 10: 507-519.
    CrossRefDirect Link

  10. Dolle, R.E., 2001. Comprehensive survey of combinatorial library synthesis: 2000. J. Comb. Chem., 3: 477-517.
    CrossRefDirect Link

  11. Drews, J., 2000. Drug discovery: A historical perspective. Science, 287: 1960-1964.
    CrossRefDirect Link

  12. Thomas, G., 2011. Medicinal Chemistry: An Introduction. 2nd Edn., John Wiley & Sons, New York, USA., ISBN-13: 9781119965428, Pages: 646.

  13. Newman, D.J., G.M. Cragg and K.M. Snader, 2000. The influence of natural products upon drug discovery. Natl. Prod. Rep., 17: 215-234.
    CrossRefPubMedDirect Link

  14. Lombardino, J.G. and J.A. Lowe, 2004. The role of the medicinal chemist in drug discovery-then and now. Nat. Rev. Drug Discov., 3: 853-862.
    CrossRefDirect Link

  15. Gershell, L.J. and J.H. Atkins, 2003. A brief history of novel drug discovery technologies. Nat. Rev. Drug Discov., 2: 321-327.
    CrossRefDirect Link

  16. Kayser, O. and H. Warzecha, 2012. Pharmaceutical Biotechnology: Drug Discovery and Clinical Applications. John Wiley & Sons, New York, USA., ISBN-13: 9783527329946, Pages: 647.

  17. Dudzinski, D.M. and A.S. Kesselheim, 2008. Scientific and legal viability of follow-on protein drugs. N. Engl. J. Med., 358: 843-849.
    CrossRefPubMedDirect Link

  18. Tucker, J., S. Yakatan and S. Yakatan, 2008. Biogenerics 2007: How far have we come? J. Commer. Biotechnol., 14: 56-64.
    CrossRefDirect Link

  19. Qadir, M.I. and A. Abid, 2017. Acute HIV infection: Advances in mechanisms and prophylactic therapeutic management. Crit. Rev. Eukaryotic Gene Express., 27: 79-90.
    CrossRefDirect Link

  20. Triggle, D.J., 2006. Drug discovery and delivery in the 21st century. Med. Principles Pract., 16: 1-14.
    CrossRefDirect Link

  21. Pina, A.S., A. Hussain and A.C.A. Roque, 2010. An Historical Overview of Drug Discovery. In: Ligand-Macromolecular Interactions in Drug Discovery: Methods and Protocols, Roque, A.C.A. (Ed.). Chapter 1, Humana Press, Totowa, NJ., USA., ISBN: 978-1-60761-243-8, pp: 3-12.

  22. Yang, Y., S.J. Adelstein and A.I. Kassis, 2009. Target discovery from data mining approaches. Drug Discov. Today, 14: 147-154.
    CrossRefDirect Link

  23. Bertram, L. and R.E. Tanzi, 2008. Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses. Nat. Rev. Neurosci., 9: 768-778.
    CrossRefDirect Link

  24. Cox, J.J., F. Reimann, A.K. Nicholas, G. Thornton and E. Roberts et al., 2006. An SCN9A channelopathy causes congenital inability to experience pain. Nature, 444: 894-898.
    CrossRefDirect Link

  25. Yang, Y., Y. Wang, S. Li, Z. Xu and H. Li et al., 2004. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J. Med. Genet., 41: 171-174.
    CrossRefDirect Link

  26. Kurosawa, G., Y. Akahori, M. Morita, M. Sumitomo and N. Sato et al., 2008. Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic. Proc. Natl. Acad. Sci. USA., 105: 7287-7292.
    CrossRefDirect Link

  27. Henning, S.W. and G. Beste, 2002. Loss-of-function strategies in drug target validation. Curr. Drug Discov., 5: 17-21.

  28. Honore, P., K. Kage, J. Mikusa, A.T. Watt and J.F. Johnston et al., 2002. Analgesic profile of intrathecal P2X3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain, 99: 11-19.
    CrossRefDirect Link

  29. Peet, N.P., 2003. What constitutes target validation? Targets, 2: 125-127.
    CrossRefDirect Link

  30. Chessell, I.P., J.P. Hatcher, C. Bountra, A.D. Michel and J.P. Hughes et al., 2005. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain, 114: 386-396.
    CrossRefDirect Link

  31. Abell, A.N., J.A. Rivera-Perez, B.D. Cuevas, M.T. Uhlik and S. Sather et al., 2005. Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryo. Mol. Cell. Biol., 25: 8948-8959.
    CrossRefDirect Link

  32. Castanotto, D. and J.J. Rossi, 2009. The promises and pitfalls of RNA-interference-based therapeutics. Nature, 457: 426-433.
    CrossRefDirect Link

  33. Whitehead, K.A., R. Langer and D.G. Anderson, 2009. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov., 8: 129-138.
    CrossRefDirect Link

  34. Ugolini, G., S. Marinelli, S. Covaceuszach, A. Cattaneo and F. Pavone, 2007. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc. Natl. Acad. Sci. USA., 104: 2985-2990.
    CrossRefDirect Link

  35. Zanders, E.D., D.S. Bailey and P.M. Dean, 2002. Probes for chemical genomics by design. Drug Discov. Today, 7: 711-718.
    CrossRefDirect Link

  36. Fox, S., S. Farr-Jones, L. Sopchak, A. Boggs, H.W. Nicely, R. Khoury and M. Biros, 2006. High-throughput screening: update on practices and success. J. Biomol. Screening, 11: 864-869.
    CrossRefDirect Link

  37. Boppana, K., P.K. Dubey, S.A.R.P. Jagarlapudi, S. Vadivelan and G. Rambabu, 2009. Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models. Eur. J. Med. Chem., 44: 3584-3590.
    CrossRefDirect Link

  38. McInnes, C., 2007. Virtual screening strategies in drug discovery. Curr. Opin. Chem. Biol., 11: 494-502.
    CrossRefDirect Link

  39. Frearson, J.A. and I.T. Collie, 2009. HTS and hit finding in academia-from chemical genomics to drug discovery. Drug Discov. Today, 14: 1150-1158.
    CrossRefDirect Link

  40. Dunne, A., M. Jowett and S. Rees, 2009. Use of Primary Human Cells in High-Throughput Screens. In: High Throughput Screening: Methods and Protocols, Janzen, W.P. and P. Bernasconi (Eds.). 2nd Edn., Chapter 12, Humana Press, Totowa, NJ., USA., ISBN: 978-1-60327-257-5, pp: 239-257.

  41. Hughes, B., 2010. 2009 FDA drug approvals. Nat. Rev. Drug Discov., 9: 89-92.
    CrossRefDirect Link

  42. Drake, J.M. and B.D. Griffen, 2010. Early warning signals of extinction in deteriorating environments. Nature, 467: 456-459.
    CrossRefDirect Link

  43. Maqbool, F., S. Mostafalou, H. Bahadar and M. Abdollahi, 2016. Review of endocrine disorders associated with environmental toxicants and possible involved mechanisms. Life Sci., 145: 265-273.
    CrossRefDirect Link

  44. Eichler, H.G., B. Aronsson, E. Abadie and T. Salmonson, 2010. New drug approval success rate in Europe in 2009. Nat. Rev. Drug Discov., 9: 355-356.
    CrossRefDirect Link

  45. Mullard, A., 2016. 2015 FDA drug approvals. Nat. Rev. Drug Discov., 15: 73-76.
    CrossRefDirect Link

  46. Brown, M.J., 2009. The impact of clinical trials legislation on clinical pharmacology: Problems and solutions. Br. J. Clin. Pharmacol., 67: 487-493.
    CrossRefDirect Link

  47. Sherman, R.E., J. Li, S. Shapley, M. Robb and J. Woodcock, 2013. Expediting drug development-the FDA's new “breakthrough therapy” designation. N. Engl. J. Med., 369: 1877-1880.
    CrossRefDirect Link

  48. Michelini, E., L. Cevenini, L. Mezzanotte, A. Coppa and A. Roda, 2010. Cell-based assays: Fuelling drug discovery. Anal. Bioanal. Chem., 398: 227-238.
    CrossRefDirect Link

  49. Moore, K. and S. Rees, 2001. Cell-based versus isolated target screening: How lucky do you feel? J. Biomol. Screening, 6: 69-74.
    CrossRefDirect Link

  50. Zhang, J.H., T.D.Y. Chung and K.R. Oldenburg, 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen., 4: 67-73.
    CrossRefDirect Link

  51. Stables, J., L.C. Mattheakis, R. Chang and S. Rees, 2000. Recombinant aequorin as reporter of changes in intracellular calcium in mammalian cells. Methods Enzymol., 327: 456-471.
    CrossRefDirect Link

  52. Schmidt, B.J., J.A. Papin and C.J. Musante, 2013. Mechanistic systems modeling to guide drug discovery and development. Drug Discov. Today, 18: 116-127.
    CrossRefDirect Link

  53. Maqbool, F., M. Safavi, H. Bahadar, M. Rahimifard, K. Niaz and M. Abdollahi, 2015. Discovery approaches for novel dyslipidemia drugs. Curr. Drug Discov. Technol., 12: 90-116.
    Direct Link

  54. Mai, A., 2014. Targeting epigenetics in drug discovery. ChemMedChem, 9: 415-417.
    CrossRefDirect Link

  55. Burkhard, J.A., G. Wuitschik, M. Rogers-Evans, K. Muller and E.M. Carreira, 2010. Oxetanes as versatile elements in drug discovery and synthesis. Angewandte Chemie Int. Edn., 49: 9052-9067.
    CrossRefDirect Link

  56. Dai, H.X., A.F. Stepan, M.S. Plummer, Y.H. Zhang and J.Q. Yu, 2011. Divergent C-H functionalizations directed by sulfonamide pharmacophores: Late-stage diversification as a tool for drug discovery. J. Am. Chem. Soc., 133: 7222-7228.
    CrossRefDirect Link

  57. Leach, A.G., H.D. Jones, D.A. Cosgrove, P.W. Kenny and L. Ruston et al., 2006. Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure. J. Med. Chem., 49: 6672-6682.
    CrossRefDirect Link

  58. Keefer, C.E., G. Chang and G.W. Kauffman, 2011. Extraction of tacit knowledge from large ADME data sets via pairwise analysis. Bioorg. Med. Chem., 19: 3739-3749.
    CrossRefDirect Link

  59. Friesner, R.A., R.B. Murphy, M.P. Repasky, L.L. Frye and J.R. Greenwood et al., 2006. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem., 49: 6177-6196.
    CrossRefDirect Link

  60. Newman, D.J. and G.M. Cragg, 2012. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod., 75: 311-335.
    CrossRefDirect Link

  61. Bauer, A. and M. Bronstrup, 2014. Industrial natural product chemistry for drug discovery and development. Nat. Prod. Rep., 31: 35-60.
    CrossRefDirect Link

  62. Ritchie, T.J. and S.J.F. Macdonald, 2009. The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design? Drug Discov. Today, 14: 1011-1020.
    CrossRefDirect Link

  63. Lovering, F., J. Bikker and C. Humblet, 2009. Escape from flatland: Increasing saturation as an approach to improving clinical success. J. Med. Chem., 52: 6752-6756.
    CrossRefDirect Link

  64. Nicolaou, K.C. and T. Montagnon, 2008. Molecules that Changed the World. Wiley-VCH, Weinheim, Germany, ISBN: 978-3-527-30983-2, Pages: 385.

  65. Stepan, A.F., G.W. Kauffman, C.E. Keefer, P.R. Verhoest and M. Edwards, 2013. Evaluating the differences in cycloalkyl ether metabolism using the design parameter “lipophilic metabolism efficiency” (LipMetE) and a matched molecular pairs analysis. J. Med. Chem., 56: 6985-6990.
    CrossRefDirect Link

  66. Stepan, A.F., K. Karki, W.S. McDonald, P.H. Dorff and J.K. Dutra et al., 2011. Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors. J. Med. Chem., 54: 7772-7783.
    CrossRefDirect Link

  67. Muller, K., C. Faeh and F. Diederich, 2007. Fluorine in pharmaceuticals: Looking beyond intuition. Science, 317: 1881-1886.
    CrossRefDirect Link

  68. Hernandes, M.Z., S.M.T. Cavalcanti, D.R.M. Moreira, W.F. de Azevedo Jr. and A.C.L. Leite, 2010. Halogen atoms in the modern medicinal chemistry: Hints for the drug design. Curr. Drug Targets, 11: 303-314.
    CrossRefDirect Link

  69. Schreiber, S.L., 2011. Organic synthesis toward small-molecule probes and drugs. Proc. Natl. Acad. Sci. USA., 108: 6699-6702.
    CrossRefDirect Link

  70. Nicolaou, K.C., C.R. Hale, C. Nilewski and H.A. Ioannidou, 2012. Constructing molecular complexity and diversity: Total synthesis of natural products of biological and medicinal importance. Chem. Soc. Rev., 41: 5185-5238.
    CrossRefDirect Link

  71. Sellers, W.R., 2011. A blueprint for advancing genetics-based cancer therapy. Cell, 147: 26-31.
    CrossRefDirect Link

  72. Nicolaou, K.C., 2014. Advancing the drug discovery and development process. Angewandte Chemie Int. Edn., 53: 9128-9140.
    CrossRefDirect Link

  73. Williams, S.A., W.C. Anderson, M.T. Santaguida and S.J. Dylla, 2013. Patient-derived xenografts, the cancer stem cell paradigm and cancer pathobiology in the 21st century. Lab. Invest., 93: 970-982.
    CrossRefDirect Link

  74. De Palma, M. and D. Hanahan, 2012. The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities. Mol. Oncol., 6: 111-127.
    CrossRefDirect Link

  75. Slusher, B.S., P.J. Conn, S. Frye, M. Glicksman and M. Arkin, 2013. Bringing together the academic drug discovery community. Nat. Rev. Drug Discov., 12: 811-812.
    CrossRefDirect Link

  76. Paul, S.M., D.S. Mytelka, C.T. Dunwiddie, C.C. Persinger, B.H. Munos, S.R. Lindborg and A.L. Schacht, 2010. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov., 9: 203-214.
    CrossRefDirect Link

Keywords


  • monoclonal antibodies
  • Targeted-drug discovery
  • drug design
  • spectroscopy
  • clinical trials
  • toxicological studies

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved